KSQ Therapeutics states that it is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by a proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a more comprehensive understanding of disease biology. The quality of these insights enables their scientists to identify and validate high-confidence, patient-tailored drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from KSQ Therapeutics or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.